

Alisol A 24-acetate Datasheet

4th Edition (Revised in July, 2016)

[Product Information]

Name: Alisol A 24-acetate

Catalog No.: CFN90198

Cas No.: 18674-16-3


Purity: >=98%

M.F: C₃₂H₅₂O₆

M.W: 532.75

Physical Description: White powder

Synonyms: (8 α ,9 β ,14 β ,23S,24R)-11 β ,23,25-Trihydroxy-24-Acetoxydammar
-13(17)-en-3-one;24-O-Acetylalisol A;Alisol A 24-monoacetate.



[Intended Use]

1. Reference standards;
2. Pharmacological research;
3. Synthetic precursor compounds;
4. Intermediates & Fine Chemicals;
5. Others.

[Source]

The tubers of *Alisma plantago-aquatica* Linn.

[Biological Activity or Inhibitors]

Alisol A 24-acetate, isolated from the rhizome of *Alismatis plantago-aquaticae* L. var. *orientale* Samuelson (Alismataceae), has anti-complement activity against the classical pathway of the complement system with IC₅₀ values of 130 µM. ^[1]

Alisol A 24-acetate can effectively prevent bone loss in ovariectomized (OVX) mice, and that it can be considered a potential therapeutic for the treatment of postmenopausal osteoporosis. ^[2]

Alisol A-24-monoacetate has hypocholesterolemic effect. ^[3]

Alisol A 24-acetate can inhibit RANKL-mediated osteoclast differentiation by downregulating NFATc1, which plays an essential role in osteoclast differentiation; it also inhibits the expression of DC-STAMP and cathepsin K, which are related to cell-cell fusion of osteoclasts and bone resorption, respectively, therefore, alisol A 24-acetate could be developed as a new structural scaffold for inhibitors of osteoclast differentiation in order to develop new drugs against osteoporosis. ^[4]

Alisol A 24-acetate has antibacterial activity. ^[5]

[Solvent]

Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.

[HPLC Method]^[6]

HPLC-ELSD:

Mobile phase: Acetonitrile-H₂O=75:25;

Flow rate: 0.8 ml/min;

Column temperature: Room Temperature;

Drift tube temperature: 82 °C;

Flow rate of gas : 2.0 L/min;

Carrier gas: N₂.

[Storage]

2-8°C, Protected from air and light, refrigerate or freeze.

[References]

- [1] Sang M L, Kim J H, Zhang Y, *et al. Arch. Pharm. Res.*, 2003, 26(6):463-5.
- [2] Hwang Y H, Kang K Y, Lee S J, *et al. Molecules*, 2016, 21(1):74.
- [3] Imai Y, Matsumura H, Aramaki Y. *Jap. J. Pharmacol.*, 1970, 20(2):222-8.
- [4] Kim K J, Leutou A S, Yeon J T, *et al. Int. J. Endocrinol.*, 2015, 2015(10):132436.
- [5] Jin H G, Jin Q, Kim A R, *et al. Arch. Pharm. Res.*, 2012, 35(11):1919-26.
- [6] Chen J Z. *Chinese Journal of Pharmaceutical Analysis*, 2007, 27(5):721-3.

[Contact]

Address:

S5-3 Building, No. 111, Dongfeng Rd.,
Wuhan Economic and Technological Development Zone,
Wuhan, Hubei 430056,
China

Email: info@chemfaces.com

Tel: +86-27-84237783

Fax: +86-27-84254680

Web: www.chemfaces.com

Tech Support: service@chemfaces.com